...
首页> 外文期刊>Neurogastroenterology and motility >Corrigendum to Attenuation of Clostridium difficile toxin-induced damage to epithelial barrier by ecto-5'-nucleotidase (CD73) and adenosine receptor signaling [Neurogastroenterol Motil 25 (2013) e441-e453]
【24h】

Corrigendum to Attenuation of Clostridium difficile toxin-induced damage to epithelial barrier by ecto-5'-nucleotidase (CD73) and adenosine receptor signaling [Neurogastroenterol Motil 25 (2013) e441-e453]

机译:ecto-5'-核苷酸酶(CD73)和腺苷受体信号转导对艰难梭菌毒素诱导的上皮屏障损害的更正[Neurogastroenterol Motil 25(2013)e441-e453]

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The combination of efficacious treatment against bacterial infections and mitigation of antibiotic resistance amplification in gut microbiota is a major challenge for antimicrobial therapy in food-producing animals. In rats, we evaluated the impact of cefquinome, a fourth-generation cephalosporin, on both Klebsiella pneumoniae lung infection and intestinal flora harboring CTX-M-producing Enterobacteriaceae. Germfree rats received a fecal flora specimen from specific-pathogen-free pigs, to which a CTX-M-producing Escherichia coli strain had been added. K. pneumoniae cells were inoculated in the lungs of these gnotobiotic rats by using either a low (105 CFU) or a high (109 CFU) inoculum. Without treatment, all animals infected with the low or high K. pneumoniae inoculum developed pneumonia and died before 120 h postchallenge. In the treated groups, the low-inoculum rats received a 4-day treatment of 5 mg/kg of body weight cefquinome beginning at 24 h postchallenge (prepatent phase of the disease), and the high-inoculum rats received a 4-day treatment of 50 mg/kg cefquinome beginning when the animals expressed clinical signs of infection (patent phase of the disease). The dose of 50 mg/kg targeting the high K. pneumoniae inoculum cured all the treated rats and resulted in a massive amplification of CTX-M-producing Enterobacteriaceae. A dose of 5 mg/kg targeting the low K. pneumoniae inoculum cured all the rats and averted an outbreak of clinical disease, all without any amplification of CTX-M-producing Enterobacteriaceae. These findings might have implications for the development of new antimicrobial treatment strategies that ensure a cure for bacterial infections while avoiding the amplification of resistance genes of human concern in the gut microbiota of food-producing animals.
机译:对抗细菌感染的有效治疗和减轻肠道菌群中抗生素耐药性扩增的结合是食品生产动物中抗菌治疗的主要挑战。在大鼠中,我们评估了第四代头孢菌素头孢喹啉对肺炎克雷伯菌肺部感染和带有产生CTX-M的肠杆菌科的肠道菌群的影响。无病大鼠从无特定病原体的猪中获得粪便菌群标本,并向其中添加了产生CTX-M的大肠杆菌菌株。通过使用低(105 CFU)或高(109 CFU)接种物,将这些肺炎克雷伯菌细胞接种在这些致生病大鼠的肺中。未经治疗,所有感染了低或高肺炎克雷伯菌的动物均会出现肺炎,并在攻击后120小时之前死亡。在治疗组中,低眼病大鼠在攻击后24小时(疾病的患病阶段)开始接受5毫克/千克体重的头孢喹诺酮治疗4天,而高眼病大鼠接受4天治疗当动物表现出感染的临床体征(疾病的专利期)时,开始服用50 mg / kg头孢喹诺酮。针对高肺炎克雷伯菌接种物的50 mg / kg剂量治愈了所有治疗的大鼠,并导致产生CTX-M的肠杆菌科细菌大量扩增。针对低肺炎克雷伯菌接种物的5 mg / kg剂量治愈了所有大鼠,并避免了临床疾病的爆发,所有这些都没有产生CTX-M的肠杆菌科细菌的任何扩增。这些发现可能对开发新的抗菌治疗策略具有重要意义,该策略可确保治愈细菌感染,同时又避免了人类关注的食品生产动物肠道菌群中耐药基因的扩增。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号